COST EFFECTIVENESS OF CETUXIMAB AND PANITUMUMAB FOR FIRST-LINE RAS WT METASTATIC COLORECAL CANCER

被引：1
|
作者：
Tikhonova, I [1 ]
Hoyle, M. [1 ]
Snowsill, T. [1 ]
Crathorne, L. [1 ]
Varley-Campbell, J. [1 ]
Peters, J. [1 ]
Briscoe, S. [1 ]
Bond, M. [1 ]
Huxley, N. [1 ]
机构：
[1] Univ Exeter, Exeter, Devon, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1612
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN113
引用
收藏
页码：A154 / A154
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB FOR FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN WT RAS PATIENTS IN SPAIN
    Suarez, J.
    VALUE IN HEALTH, 2015, 18 (07) : A460 - A460
  • [2] COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB AS FIRST-LINE THERAPIES FOR METASTATIC COLORECTAL CANCER IN SPAIN
    Moreno, V
    Martinez-Amores, B.
    Barriuso, J.
    Mezquita, L.
    Ibanez de Caceres, I.
    Ayuso, A.
    Pena, J. M.
    Perona, R.
    Grande, E.
    Belda-Iniesta, C.
    VALUE IN HEALTH, 2012, 15 (07) : A421 - A422
  • [3] Cost-effectiveness analysis of cetuximab and panitumumab as first-line metastatic colorectal cancer therapies in Spain
    Moreno, Victor
    Martinez-Amores, Brezo
    Barriuso, Jorge
    Mezquita, Laura
    Ibanez de Caceres, Inmaculada
    Ayuso Sacido, Angel
    Maria Pena, Jose
    Perona, Rosario
    Belda-Iniesta, Cristobal
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] COST-EFFECTIVENESS OF BEVACIZUMAB VERSUS CETUXIMAB VERSUS PANITUMUMAB COMBINED WITH FIRST-LINE FOLFOX FOR METASTATIC COLORECTAL CANCER IN BRAZIL
    Sasse, Andre
    Carvalho, Adriana
    ANNALS OF ONCOLOGY, 2012, 23 : 100 - 100
  • [5] Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza Ahmed Mohamed
    Saleh, Khaldoon
    Tashkandi, Emad
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 67 - 75
  • [6] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Fakih, Marwan G.
    Knox, Hediyyih N.
    Maglinte, Gregory A.
    Hjelmgren, Jonas
    Barber, Beth
    Schwartzberg, Lee S.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
  • [7] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Irina A. Tikhonova
    Nicola Huxley
    Tristan Snowsill
    Louise Crathorne
    Jo Varley-Campbell
    Mark Napier
    Martin Hoyle
    PharmacoEconomics, 2018, 36 : 837 - 851
  • [8] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Tikhonova, Irina A.
    Huxley, Nicola
    Snowsill, Tristan
    Crathorne, Louise
    Varley-Campbell, Jo
    Napier, Mark
    Hoyle, Martin
    PHARMACOECONOMICS, 2018, 36 (07) : 837 - 851
  • [9] Cost-effectiveness of cetuximab, bevacizumab, and panitumumab in first-line treatment of metastatic colorectal cancer (mCRC) for patients with KRAS wild-type (wt) tumors in the United Kingdom
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL
    dos Santos, R. F.
    Riveros, B. S.
    Nita, M. E.
    Pedro, G. O.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A739
12345